NCT04722679View on ClinicalTrials.gov

A Study to Collect Information on the Characteristics of Elderly Belgian Patients With NVAF That Are Treated With a NOAC for This Indication With a Special Focus on Their Fear of Bleeding While Using a NOAC vs the Clinical Benefit of a NOAC of Thrombosis/Stroke Prevention.

CompletedOBSERVATIONAL
Enrollment

103

Participants

Timeline

Start Date

May 11, 2021

Primary Completion Date

December 31, 2021

Study Completion Date

January 3, 2022

Conditions
Non-Valvular Atrial Fibrillation
Interventions
DRUG

Non-VKA Oral Anticoagulants (NOAC)

Follow clinical practice.

Trial Locations (1)

Unknown

Many Locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT04722679 - A Study to Collect Information on the Characteristics of Elderly Belgian Patients With NVAF That Are Treated With a NOAC for This Indication With a Special Focus on Their Fear of Bleeding While Using a NOAC vs the Clinical Benefit of a NOAC of Thrombosis/Stroke Prevention. | Biotech Hunter | Biotech Hunter